Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: A multi-modality molecular imaging approach to therapeutic assessment

British Journal of Cancer

Volumn 101, Issue 9, 2009, Pages 1565-1573

  Byrne, A T ^a,b   O'Connor, A E ^a   Hall, M ^a   Murtagh, J ^a   O'Neill, K ^a   Curran, K M ^a   Mongrain, K ^c   Rousseau, J A ^c   Lecomte, R ^c   McGee, S ^a   Callanan, J J ^a   O'Shea, D F ^a   Gallagher, W M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c UNIVERSITÉ DE SHERBROOKE   (Canada)

Author keywords

BF2 chelated tetraaryl azadipyrromethene; Biodistribution; Drug efficacy; Molecular imaging; Photodynamic therapy; Vascular targeting

Indexed keywords

ADMP 06; ADPM 06; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; PENTETIC ACID; PHOTOSENSITIZING AGENT; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER INHIBITION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; EMBRYO; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VIVO STUDY; IRRADIATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DISTRIBUTION; PHOTODYNAMIC THERAPY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; TISSUE METABOLISM; TOXICITY TESTING; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

EID: 70350654364     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605247     Document Type: Article

References (20)

1. Berard V, Lecomte R, van Lier JE (2006a) Positron emission tomography imaging of tumor response after photodynamic therapy. J Environ Pathol Toxicol Oncol 25: 239-249
2. Berard V, Rousseau JA, Cadorette J, Hubert L, Bentourkia M, van Lier JE, Lecomte R (2006b) Dynamic imaging of transient metabolic processes by small-animal PET for the evaluation of photosensitizers in photodynamic therapy of cancer. J Nucl Med 47: 1119-1126
3. Chen B, Pogue BW, Hoopes PJ, Hasan T (2006) Vascular and cellular targeting for photodynamic therapy. Crit Rev Eukaryot Gene Expr 16: 279-305
4. Gallagher WM, Allen LT, O'Shea C, Kenna T, Hall M, Gorman A, Killoran J, O'Shea DF (2005) A potent nonporphyrin class of photodynamic therapeutic agent: cellular localisation, cytotoxic potential and influence of hypoxia. Br J Cancer 92: 1702-1710
5. Gorman A, Killoran J, O'Shea C, Kenna T, Gallagher WM, O'Shea DF (2004) In vitro demonstration of the heavy-atom effect for photodynamic therapy. J Am Chem Soc 126: 10619-10631
6. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y (2003) Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI. Nat Med 9: 1327-1331
7. Haider MA, Davidson SR, Kale AV, Weersink RA, Evans AJ, Toi A, Gertner MR, Bogaards A, Wilson BC, Chin JL, Elhilali M, Trachtenberg J (2007) Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide Radiology 244: 196-204
8. Hamblin MR, Hasan T (2004) Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 3: 436-450
9. Huang Z, Haider MA, Kraft S, Chen Q, Blanc D, Wilson BC, Hetzel FW (2006) Magnetic resonance imaging correlated with the histopatho-logical effect of Pd-bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland. Lasers Surg Med 38: 672-681
10. Kossodo S, LaMuraglia GM (2001) Clinical potential of photodynamic therapy in cardiovascular disorders. Am J Cardiovasc Drugs 1: 15-21
11. Lapointe D, Brasseur N, Cadorette J, La Madeleine C, Rodrigue S, van Lier JE, Lecomte R (1999) High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice. J Nucl Med 40: 876-882
12. Lecomte R, Cadorette J, Rodrigue S, Lapointe D, Rouleau D, Bentourkia M, Yao R, Msaki P (1996) Initial results from the Sherbrooke avalanche photodiode positron tomography. IEEE Trans Nucl Sci 43: 1952-1957
13. McDonnell SO, Hall MJ, Allen LT, Byrne A, Gallagher WM, O'Shea DF (2005) Supramolecular photonic therapeutic agents. J Am Chem Soc 127: 16360-16361
14. Palumbo G (2007) Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin Drug Deliv 4: 131-148
15. Schmidt-Erfurth U, Sacu S (2008) Early Retreatment Study Group. Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. Ophthalmology 115: 134-140
16. Seshadri M, Bellnier DA, Vaughan LA, Spernyak JA, Mazurchuk R, Foster TH, Henderson BW (2008) Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin Cancer Res 14: 2796-2805
17. Trachtenberg J, Bogaards A, Weersink RA, Haider MA, Evans A, McCluskey SA, Scherz A, Gertner MR, Yue C, Appu S, Aprikian A, Savard J, Wilson BC, Elhilali M (2007) Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J Urol 178: 1974-1979
18. Trachtenberg J, Weersink RA, Davidson SR, Haider MA, Bogaards A, Gertner MR, Evans A, Scherz A, Savard J, Chin JL, Wilson BC, Elhilali M (2008) Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int 102: 556-562
19. Triesscheijn M, Baas P, Schellens JH, Stewart FA (2006) Photodynamic therapy in oncology. Oncologist 11: 1034-1044
20. Wormald R, Evans J, Smeeth L, Henshaw K (2007) Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst Rev CD002030